Source:http://linkedlifedata.com/resource/pubmed/id/18037776
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
9
|
pubmed:dateCreated |
2007-11-26
|
pubmed:abstractText |
In guidelines, a combination therapy of two or more antihypertensives is recommended for treatment of hypertension where monotherapy is ineffective. Although diuretics or calcium channel blockers are commonly used as add-ons to angiotensin receptor blocker (ARB), the most effective and safe combination has not been established. In this randomized 4-month study, the efficacy and safety were compared between an ARB/diuretics (losartan/hydrochlorothiazide [HCTZ]) combination and the most prescribed combination, ARB/calcium channel blocker (candesartan/amlodipine) in hypertensive patients for whom 8 mg/day of candesartan proved ineffective. After 36 patients were recruited and allocated into two groups, changes in blood pressure (BP) and laboratory values were analyzed in 31 patients: 16 patients received losartan (50 mg/day)/HCTZ (12.5 mg/day) (L/H group), and 15 patients received candesartan (8 mg/day)/amlodipine (5 mg/day) (C/A group) after 5 patients were withdrawn. After 4 months, L/H significantly (p<0.001) reduced mean systolic BP (SBP)/diastolic BP (DBP) from baseline 160/89 +/- 13/11 mmHg to 140/80 +/- 9/8 mmHg, and C/A reduced BP from 161/90 +/- 10/11 mmHg to 141/79 +/- 10/7 mmHg. The efficacy in reducing BP was similar between the two combination therapies. L/H significantly reduced serum potassium, but within the normal range, and did not increase serum uric acid or serum triglyceride. With L/H, the percentage of patients who attained the BP goal in SBP was higher in elderly patients than in younger patients. As L/H is more cost-effective than candesartan/amlodipine and has fewer adverse effects on uric acid and other metabolic parameters than diuretic monotherapy, it is concluded to be useful for the management of hypertension.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Amlodipine,
http://linkedlifedata.com/resource/pubmed/chemical/Antihypertensive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Benzimidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Diuretics,
http://linkedlifedata.com/resource/pubmed/chemical/Hydrochlorothiazide,
http://linkedlifedata.com/resource/pubmed/chemical/Losartan,
http://linkedlifedata.com/resource/pubmed/chemical/Tetrazoles,
http://linkedlifedata.com/resource/pubmed/chemical/candesartan
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0916-9636
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
30
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
831-7
|
pubmed:meshHeading |
pubmed-meshheading:18037776-Aged,
pubmed-meshheading:18037776-Amlodipine,
pubmed-meshheading:18037776-Antihypertensive Agents,
pubmed-meshheading:18037776-Asian Continental Ancestry Group,
pubmed-meshheading:18037776-Benzimidazoles,
pubmed-meshheading:18037776-Diuretics,
pubmed-meshheading:18037776-Drug Therapy, Combination,
pubmed-meshheading:18037776-Female,
pubmed-meshheading:18037776-Humans,
pubmed-meshheading:18037776-Hydrochlorothiazide,
pubmed-meshheading:18037776-Hypertension,
pubmed-meshheading:18037776-Japan,
pubmed-meshheading:18037776-Losartan,
pubmed-meshheading:18037776-Male,
pubmed-meshheading:18037776-Middle Aged,
pubmed-meshheading:18037776-Prospective Studies,
pubmed-meshheading:18037776-Tetrazoles,
pubmed-meshheading:18037776-Treatment Outcome
|
pubmed:year |
2007
|
pubmed:articleTitle |
Effectiveness of add-on low-dose diuretics in combination therapy for hypertension: losartan/hydrochlorothiazide vs. candesartan/amlodipine.
|
pubmed:affiliation |
Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Tokyo, Japan.
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial
|